Journal of Leukemia

Journal of Leukemia
Open Access

ISSN: 2329-6917

+44 1300 500008

Ting Yang

Ting Yang
Union Hospital, No. 29 Xinquan Road, Fuzhou, Fujian 350001,
Bolivarian Rep. of Venezuela

  • Review Article
    Treatment Advances for Burkitt Lymphoma
    Author(s): Issa Hajji Ally, Ting Yang and Jianda HuIssa Hajji Ally, Ting Yang and Jianda Hu

    Burkitt Lymphoma (BL) is an uncommon but highly aggressive B-cell Non-Hodgkin Lymphoma (NHL). It is a subtype of mature B-cell lymphoma and can be treated successfully within a short period via high-intensity chemotherapeutic regimens. Diagnosis and initial work-up must be completed rapidly to begin treatment due to high proliferation. BL is associated with the Epstein-Barr Virus (EBV) and with a chromosomal translocation that activates the c-MYC gene. However, by implementing chemotherapy regimens, complete remission and overall survival for young patients with BL remains high. In contrast, in elderly patients and those with relapsed/refractory disease, the prognosis remains a medical challenge. Rituximab, the chimeric monoclonal antibody against CD20, has improved the clinical management of B-cell malignancies. Because BL expresses a CD20 positive marker in their cell surface.. View More»
    DOI: 10.35248/2329-6917.19.7.255

    Abstract PDF

Relevant Topics